Black Diamond Therapeutics Inc. (BDTX)
NASDAQ: BDTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BDTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $75.28M
- EPS (TTM)
- -$0.77
- Dividend yield
- None
- 52-week range
- 1.31 – 3.97
- Day range
- 1.31 – 1.41
- Volume / Avg
- 663.19K / 697.70K
- Beta
- —
- Shares outstanding
- 57.47M
52-week range
BDTX stock today
Shares of Black Diamond Therapeutics (BDTX) finished lower on Nov 20 at $1.31, a drop of 5.76% or $0.08 per share, versus the S&P 500's 3.70% decline. At this level, BDTX sits near the bottom of its 52-week range of $1.31 to $3.97: 67.0% below the high, set on May 20, 2026 and 0.0% above the low. BDTX is down 46.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.5%.
Black Diamond Therapeutics has posted a net loss over the last twelve months (EPS of -$0.77), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Black Diamond Therapeutics
Company profileBlack Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Mark A. Velleca M.D., Ph.D.
- Headquarters
- Cambridge, MA
- Employees
- 21
- IPO year
- 2020
- Website
- blackdiamondtherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Black Diamond Therapeutics generated $70.0 million in revenue, up 0.0% from fiscal 2024. Net income was $22.4 million, for a net margin of 32.0%. Operating margin was 17.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $70.00M | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $22.37M | $-69.68M | $-82.44M | $-91.17M | $-125.60M |
| EPS (diluted) | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 |
Analyst forecast
ForecastConsensus (8 analysts)
none
Avg. price target
$10.00+663.36%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.17 vs $-0.03
- Surprise
- -466.67%
BDTX news
All BDTX news- Black Diamond Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Black Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares RiseNasdaqBDTX, BRK.B
- Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate UpdateGlobeNewswire
- Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLCGlobeNewswire
Black Diamond Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRDFCardiff Oncology Inc. | 0.8528 | -4.46% | $66.34M | vs BDTX |
| TNYATenaya Therapeutics Inc. | 0.2866 | -3.99% | $65.32M | vs BDTX |
| ATRAAtara Biotherapeutics Inc. | 6.33 | -0.16% | $64.49M | vs BDTX |
| NMRANeumora Therapeutics Inc. | 0.3339 | -3.78% | $63.01M | vs BDTX |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs BDTX |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs BDTX |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs BDTX |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs BDTX |
Indexes, lists and sector
Black Diamond Therapeutics stock FAQ
What is Black Diamond Therapeutics's stock price today?
BDTX last traded at $1.31 as of Nov 20, 4:00 PM EST, down 5.76% on the day. Prices are delayed at least 15 minutes.
Who is Black Diamond Therapeutics's CEO?
Dr. Mark A. Velleca M.D., Ph.D. is the chief executive officer of Black Diamond Therapeutics Inc., which has about 21 employees.
What is the BDTX 52-week high?
The 52-week high for BDTX is $3.97 and the 52-week low is $1.31. The stock is currently 67.0% below its high.